- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Characteristics Distinguishing CLL and SLL
Key opinion leaders open a discussion surrounding CLL and SLL, and describing unique characteristics of each disease state.
EP: 1.Clinical Characteristics Distinguishing CLL and SLL
EP: 2.Quality of Life Impacted By CLL and SLL Diagnosis and Management
EP: 3.Evaluating Current Treatment Landscape of CLL and SLL
EP: 4.Unmet Needs In CLL and SLL Treatment Management
EP: 5.Indications and Considerations For BTK Inhibitor Use In CLL and SLL Management
EP: 6.Examining Safety and Efficacy of BTK Inhibitors In CLL and SLL Treatment
EP: 7.Determining Optimal CLL / SLL Therapy: Ibrutinib, Acalabrutinib and Zanubrutinib
EP: 8.Key Highlights From ASH 2023
EP: 9.Economic Burden Associated With BTK Inhibitor Use
EP: 10.Patient Education Driving BTK Inhibitor Treatment Adherence
EP: 11.Optimizing BTKi Treatment Strategies
EP: 12.Key Considerations for Treating Patients Diagnosed With CLL and SLL
This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; and Jennifer Woyach, MD.
In this video, Graff provides an overview of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), noting that they are forms of non-Hodgkin lymphoma despite the term “leukemia” being used. She explains that while CLL involves malignant lymphocytes floating in the blood and SLL involves malignant lymphocytes in the lymph nodes, many patients have a hybrid of both diseases.
Jacobs then discusses the incidence and prevalence of CLL and SLL. He states that the incidence, or number of new cases per year, of CLL is about 1% of cancer diagnoses annually in the US, and he has not seen data showing this changing over time. However, the prevalence, or number of people living with CLL, is increasing for a few reasons—the aging population, since the average age of diagnosis is around 70 years old, as well as improved treatments helping patients live longer. He notes estimates that CLL prevalence will increase by about 50% from 2015 to 2025.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Economic Burden Is Greater Among Patients With Ovarian Cancer Receiving BRCA Testing
September 4th 2025Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).
Read More
